论文部分内容阅读
目的：观察巴曲抗栓酶对脑梗死病人血液流变学及纤溶的作用。方法：６０例脑梗死病人分为３组，巴曲抗栓酶组２０例，首次给１０ＢＵ，继而隔日５ＢＵ，加入０．９％氯化钠注射液２５０ｍＬ中静脉滴注（静滴），共３次（总量２０ＢＵ）；蝮蛇抗栓酶组１８例，给精制蝮蛇抗栓酶０．５Ｕ加入０．９％氯化钠注射液２５０ｍＬ中静滴，ｑｄ×１４ｄ；右旋糖酐组２２例，给右旋糖酐４０，５００ｍＬ加丹参注射液１６ｍＬ静滴，ｑｄ×１４ｄ。结果：３组均有不同程度改善血液流变学作用；在纤溶指标方面，巴曲抗栓酶组与蝮蛇抗栓酶组均显著降低凝血因子Ｉ及增加Ｄ－二聚体（Ｄ－ｄｉｍｅｒ）作用（Ｐ＜０．０５）；巴曲抗栓酶组尚有降低α２纤溶抑制物作用（Ｐ＜０．０５）。而另２组则无；巴曲抗栓酶总有效率达８５％。３组疗效相信相仿。结论：巴曲抗栓酶降血粘度及溶栓效果好，治疗脑梗死疗效高。
Objective: To observe the effect of batroxobin on hemorrheology and fibrinolysis in patients with cerebral infarction. Methods: Sixty patients with cerebral infarction were divided into three groups. Batroxobin group (n = 20) was given for the first time to 10BU, followed by 5BU every other day by adding intravenous drip (intravenous infusion) of 0.9% sodium chloride injection 250mL 3 times (total 20BU); viper antithrombin group 18 cases, to the purified viper antithrombin enzyme 0.5U 0.9% sodium chloride injection 250mL intravenous infusion, qd × 14d; dextran group of 22 patients , Give dextran 40,500mL add Salvia injection 16mL intravenous infusion, qd × 14d. Results: The hemorheology was improved in all three groups. In terms of fibrinolysis, both the anti-fibrinolipase group and the anti-fibromycin group significantly decreased the levels of coagulation factor I and D-dimer (D- dimer (P <0.05). The antithrombotic effect of batroxobin also decreased α2 fibrinolysis inhibitor (P <0.05). While the other two groups did not; Batroxobin the total effective rate of 85%. The three groups believe similar efficacy. Conclusion: Batroxobin is effective in reducing blood viscosity and thrombolysis and treating cerebral infarction.